BioCentury
ARTICLE | Company News

Affibody, Algeta deal

May 16, 2011 7:00 AM UTC

Algeta received exclusive, worldwide rights to two Affibody carrier molecules targeting epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu) and platelet derived growth factor receptor B ...